|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
New Trump Administration, New Republican Congress: What Will the FDA’s Agenda Be in 2017?
The US has a new president, a new Congress, and almost assuredly a new agenda for the FDA — with different policies and priorities than the current administration.
What does this mean for FDA regulated industries?
Steve Grossmann — a long-time D.C. insider, who served as a Senate Health Committee Staff Director and Deputy Assistant Secretary of Health — will discuss what the FDA is doing today and what it likely will be doing under the next administration.
After attending this session you will learn:
Order today for a glimpse of what 2017 will bring for the FDA and its regulated industries.
Anyone in a position to lead an FDA-regulated company, develops a new product for regulatory approval, or is concerned about trends in FDA regulation and policy will benefit from this webinar.
Steven Grossman, President, HPS Group, LLC
Steven Grossman is President of HPS Group, LLC, a consultancy that provides strategic counsel, analysis and advocacy on regulatory and policy issues involving the U.S. Food and Drug Administration. Mr. Grossman serves on the Board of Directors of the National Organization for Rare Disorders (NORD) and sits on the board’s executive committee. He is also a founder and deputy executive director of the Alliance for a Stronger FDA, a multi-stakeholder coalition that advocates for increased resources for the FDA. Earlier in his career, Mr. Grossman was Deputy Assistant Secretary for Health at HHS and Health Staff Director and Counsel to the Senate HELP Committee.
Copyright ©2017. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing